Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia

• DOI: 10.1002/pros.23986
• Publication Date: 2020-05-01T10:30:07Z
• Authors: Petra Popovics; Wisam N. Awadallah; Sarah E. Kohrt; Thomas C. Case; Nicole L. Miller; Emily A. Ricke; Wei Huang; Marisol Ramirez‐S...; Qi Liu; Chad M. Vezina; Robert J. Matusik; William A. Ricke; Magdalena M. Grab...
• Keywords: Osteopontin; Proinflammatory cytokine; Immunostaining

Male lower urinary tract symptoms (LUTS) occur in more than half of men above 50 years age. LUTS were traditionally attributed to benign prostatic hyperplasia (BPH) and therefore the clinical terminology often uses BPH interchangeably. More recently, also linked fibrogenic inflammatory processes. We tested whether osteopontin (OPN), a proinflammatory profibrotic molecule, is increased symptomatic BPH. prostate epithelial stromal cells secrete OPN response stimuli identified downstream targets cells.Immunohistochemistry was performed on sections obtained from transition zone patients who underwent surgery (Holmium laser enucleation prostate) relieve (surgical BPH, S-BPH) or radical prostatectomy remove low-grade cancer (incidental I-BPH). Images stained tissue captured with Nuance Multispectral Imaging System histoscore, as measure staining intensity, determined inForm software. protein abundance by Western blot analysis. The ability IL-1β TGF-β1 (BHPrS-1) (NHPrE-1 BHPrE-1) enzyme-linked immunosorbent assay. Quantitative polymerase chain reaction used gene expression changes these OPN.OPN immunostaining levels abundant S-BPH I-BPH. Staining distributed across all cell types highest cells. Multiple variants immortalized stimulated secretion NHPrE-1 both BHPrS-1 Interestingly, recombinant mRNA CXCL1, CXCL2, CXCL8, PTGS2, IL6 BHPrS-1, but not lines.OPN prostates compared cytokines, acts directly drive synthesis mRNAs. Pharmacological manipulation may have potential reduce inhibiting fibrotic pathways.